Jane Street’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$989K Sell
35,700
-495,100
-93% -$12.7M ﹤0.01% 6515
2025
Q4
$11.5M Buy
530,800
+146,500
+38% +$2.89M ﹤0.01% 2156
2025
Q3
$5.81M Buy
384,300
+198,400
+107% +$2.46M ﹤0.01% 3200
2025
Q2
$2.1M Buy
185,900
+169,100
+1,007% +$1.83M ﹤0.01% 4344
2025
Q1
$170K Sell
16,800
-21,300
-56% -$230K ﹤0.01% 8564
2024
Q4
$451K Sell
38,100
-174,300
-82% -$2.06M ﹤0.01% 6996
2024
Q3
$2.45M Buy
212,400
+196,800
+1,262% +$2.24M ﹤0.01% 4067
2024
Q2
$165K Sell
15,600
-357,700
-96% -$3.92M ﹤0.01% 8523
2024
Q1
$3.93M Sell
373,300
-95,900
-20% -$1.03M ﹤0.01% 2979
2023
Q4
$5.27M Buy
469,200
+6,700
+1% +$65.3K ﹤0.01% 2773
2023
Q3
$5.4M Buy
+462,500
New +$5.23M ﹤0.01% 2508

Other funds holding ROIV

Jane Street's ROIV Position: Q1 2026 in Review

Jane Street reduced its Roivant Sciences (ROIV) stake by 22% in Q1 2026, selling an estimated $7.47M and leaving 1,020,707 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Jane Street first reported a position in ROIV in Q1 2022 and has held it in 16 quarters since. The position peaked at $41.5M in Q3 2025. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Jane Street held 1,020,707 shares of Roivant Sciences worth $28.3M as of Q1 2026.
  • Jane Street sold 290,878 Roivant Sciences shares in Q1 2026, an estimated $7.47M.
  • Roivant Sciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1489 holding.
  • Jane Street first reported a position in Roivant Sciences in Q1 2022 and has held it in 16 quarters since.
  • Jane Street's Roivant Sciences position peaked at $41.5M in Q3 2025.
  • 440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.